Portal de Periódicos da CAPES

Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992–2006

2009; Elsevier BV; Volume: 115; Issue: 2 Linguagem: Inglês

10.1016/j.ygyno.2009.07.004

1095-6859

Nana Tchabo, Susan A. McCloskey, Terry Mashtare, Chris Andrews, Anurag K. Singh, Paulette Mhawech‐Fauceglia, Kunle Odunsi, Shashikant Lele, Wainwright Jaggernauth,

Cervical Cancer and HPV Research

Objective Optimal management of early-stage uterine papillary serous carcinoma (UPSC) remains controversial. We reviewed our outcomes in this patient population. Methods The Roswell Park Cancer Institute (RPCI) tumor registry identified all patients with Stages I and IIA UPSC treated between January 1992 and June 2006. The Fisher's exact test was used to compare recurrence rates by adjuvant therapy received. Overall survival (OS) estimates were made using the Kaplan–Meier method. Results Fifty-eight patients with Stage I or IIA UPSC underwent surgery. Thirty-four patients (59%) were surgically staged. Among 21 patients with Stage IA disease, 15 received adjuvant therapy. With a median follow-up of 44.7 months, only one recurrence was observed in a patient who received adjuvant brachytherapy. The 5-year OS was 66%. Among 37 patients with Stages IB–IIA, 30 patients received adjuvant therapy. With a median follow-up of 29 months, there were 7 recurrences. The 5-year OS was 60%. Although there were no significant differences in recurrence by adjuvant therapy received, a significant OS benefit was found in those who received radiation. There was no significant difference in OS distributions of those patients who received Carboplatin/Paclitaxel chemotherapy. Conclusions Despite the limitations of our retrospective study, we have shown that even comprehensively staged early-stage UPSC patients are still at risk for recurrence despite adjuvant therapy received. Hence, all patients with this histologic diagnosis should be considered at high risk for recurrence and counseled appropriately regarding the risks and benefits of adjuvant therapy.